



PRESS RELEASE FOR IMMEDIATE USE

Dechra Veterinary Products Receives FDA Approval on Amoxicillin-Clavulanate Tablets

Dechra Veterinary Products has received FDA-CVM approval for Amoxicillin Trihydrate and Clavulanate Potassium Tablets. This approval represents the first registration Dechra has achieved through Putney's development pipeline since it acquired the US-based business earlier this year.

"The FDA-CVM approval of Amoxicillin Trihydrate and Clavulanate Potassium Tablets greatly increases Dechra's offering to our veterinary customers and will provide them with an additional option when they need to reach for a systemic antibiotic in their practice. The approval also embodies the ongoing benefit Dechra expects to bring to the veterinary market from the Putney acquisition and will further solidify our position as one of the fastest growing pharmaceutical companies in the US. This approval also represents a significant success for the Dechra R&D and Regulatory Teams based in Portland, Maine," said Mike Eldred, President of North American Operations for Dechra.

Initially, the product will be launched under Putney trade dress, however in 2017, the drug will be sold under a Dechra tradename and packaged in Dechra trade dress. Amoxicillin-Clavulanate Tablets will join the existing Dechra anti-infective portfolio that includes Cefpodoxime Proxetil Tablets, Enrofloxacin Flavored Tablets, ANIMAX[®] OINTMENT (nystatin, neomycin sulfate, thioestrepton, triamcinolone acetonide ointment), GENTACALM[®] Topical Spray (gentamicin sulfate with betamethasone valerate) and Muricin[®] (mupirocin 2%) Ointment.

Dechra expects to launch the drug within the coming weeks and product will be available for veterinarians to purchase through select veterinary distributors shortly thereafter. Please contact your Dechra representative or distributor representative for further details on availability.

Contact:

Mike Eldred
President, North American Operations
Dechra Veterinary Products
Mike.Eldred@Dechra.com

Doug Hubert
Vice President, Sales and Marketing
Dechra Veterinary Products
Doug.Hubert@Dechra.com

Dechra Veterinary Products, located in Overland Park, Kansas is the U.S. sales and marketing division of Dechra Pharmaceuticals PLC, a UK listed company dedicated to the animal healthcare market. Dechra Veterinary Products' companion animal portfolio focuses on endocrinology, dermatology, ophthalmology, anesthesia, fluid therapy, pain management and joint health support. Our brands include VETORYL[®] Capsules (trilostane), ZYCORTAL[®] Suspension (desoxycorticosterone pivalate injectable suspension), FELIMAZOLE[®] (methimazole) Coated Tablets, ANIMAX[®] OINTMENT (nystatin, neomycin sulfate, thiostrepton, triamcinolone acetonide ointment), VETROPOLYCIN[®] (bacitracin-neomycin-polymyxin) Veterinary Ophthalmic Ointment and VETROPOLYCIN[®] HC (bacitracin-neomycin-polymyxin-hydrocortisone acetate 1%) Veterinary Ophthalmic Ointment, VETIVEX[®] line of parenteral fluids, and PHYCOX[®] joint health supplements. Dechra also offers a comprehensive line of topical veterinary products including MICONAHEX+Triz[®], MALACETIC[®] and MAL-A-KET[™] brands, plus a number of injectable anesthetics, oral anti-infectives and NSAIDs. Dechra's equine portfolio includes OSPHOS[®] (clodronate injection), Orthokine[®] vet irap 10 and 60, Osteokine[®] (PRP), and EQUIDONE[®] (domperidone) Gel and PHYCOX[®] EQ joint health supplements. For more information, please visit www.dechra-us.com or call (866) 933-2472.